EMA Withdrawn: Zostavax (varicella-zoster virus (live, attenuated)) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency withdrew Zostavax, a live attenuated varicella-zoster vaccine, from the EU market. The decision date was 30 June 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Zostavax (Varicella zoster vaccine live)

Snippet

Status: Withdrawn. Therapeutic area: Herpes Zoster;Immunization. MAH: Merck Sharp & Dohme B.V.. Decision date: 30/06/2022